This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2011-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chuo-ku, JP (2011)
- Tokyo, JP (2012)
Company Filing History:
Years Active: 2011-2012
Title: Keiko Hatanaka: Innovator in Pharmaceutical Research
Introduction
Keiko Hatanaka is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical research, particularly in the development of innovative compounds for treating various diseases. With a total of 2 patents to her name, Hatanaka is recognized for her groundbreaking work in the area of Janus Kinase 3 inhibitors.
Latest Patents
Hatanaka's latest patents focus on Heterocyclic Janus Kinase 3 inhibitors. The first patent relates to a compound of the formula (I) or its salt, which is utilized as a medicament. This invention outlines the process for the preparation of the compound and its application in treating JAK3 mediated diseases. The second patent also provides a compound of formula (I) that exhibits excellent JAK3 inhibition activity. This compound is useful as an active ingredient in agents designed to treat and prevent various immune diseases, including autoimmune diseases, inflammatory diseases, and allergic diseases. The invention addresses conditions caused by undesirable cytokine signal transmission, such as organ rejection, multiple sclerosis, rheumatoid arthritis, and even Alzheimer's disease.
Career Highlights
Keiko Hatanaka is currently employed at Astellas Pharma GmbH, where she continues to advance her research in the pharmaceutical industry. Her work has been instrumental in developing new therapeutic options for patients suffering from complex diseases.
Collaborations
Hatanaka collaborates with esteemed colleagues, including Takayuki Inoue and Yutaka Nakajima. These partnerships enhance her research efforts and contribute to the innovative solutions being developed at Astellas Pharma.
Conclusion
Keiko Hatanaka is a trailblazer in the field of pharmaceutical research, with a focus on Janus Kinase 3 inhibitors. Her contributions are paving the way for new treatments that can significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile